www.lilly.com

Eli Lilly (SA) (Pty) Limited
Reg. No. 1957/000371/07
1 Petunia Street, Bryanston, 2021
Private Bag X119, Bryanston, 2021
Republic of South Africa

Telephone: (011) 510-9300 Fax: (011) 510-9301

25 October 2011

WITHDRAWAL OF XIGRIS® [drotrecogin alfa (activated)] FROM THE MARKET

SUBJECT: Xigris® [drotrecogin alfa (activated)]

Dear Healthcare Professional,

We are writing to inform you that Eli Lilly and Company is withdrawing Xigris® [drotrecogin alfa (activated)] from the market due to new clinical trial findings of lack of efficacy which call into question the benefit-risk profile of the product.

The withdrawal is effective immediately and will be completed as expeditiously as possible.

Summary

- This action is based on results from the PROWESS-SHOCK study, where overall 28-day mortality in Xigris-treated patients (N=846) was 26.4% compared to 24.2% in the placebo control group (N=834); (p=0.31, RR=1.09 [0.92-1.28]).
- While the study showed no survival benefit, no new safety findings were observed.
- The lack of efficacy seen in this trial calls into question the benefit-risk profile of Xigris for the indicated patient population.
- Patients currently receiving treatment with Xigris should have treatment discontinued. Xigris treatment should not be initiated for new patients.

Further Information

- Xigris was approved in Europe in 2002 for treatment of adult patients with severe sepsis and multiple organ failure when added to best standard care, based on results of the PROWESS study in which Xigris showed significant improvement in 28-day all-cause mortality.
- The PROWESS-SHOCK study was conducted as part of an EU regulatory commitment to further evaluate the benefit-risk profile of the drug.
- The reasons for the unexpected results in the PROWESS-SHOCK study are not known; however, a contributing factor may be advances achieved in the standard of care for patients with sepsis and septic shock in the 10 years since completion of the PROWESS trial. This is suggested by the fact that the mortality rate in placebo-treated patients in PROWESS-SHOCK was considerably lower than predicted.

Returning the Product

Check your inventory for Xigris. All strengths and package sizes are subject to this withdrawal. If Xigris is found, discontinue use and return the product to the supplier (wholesaler/distributor) from whom it was purchased. Your supplier will return the product to Eli Lilly and Company.

Details of the local distributor in Kenya:
Statim Pharmaceuticals Ltd, Corner Plaza, 4th Floor, Parklands Road, Westlands, Nairobi, Kenya, Tel: +254 20 374 1988. +254 20 374 1989,
Fax: +254 20 374 2104

Reporting Suspected Adverse Reactions

Healthcare professionals are reminded of the need to report any adverse events suspected to be associated with the use of XIGRIS to Eli Lilly (S.A.) (Pty) Ltd. e-mail: ADE_ZA@lilly.com and to the Pharmacy and Poisons Board, Lenana Road, P.O. Box 27663, Nairobi, Kenya, Tel: +254 20 271 6905, +254 20 271 6906 Ext 114, Fax: +254 20 271 3431, +254 20 271 3409, e-mail: pv@pharmacyboardkenya.org

Communication Information

Please contact Eli Lilly South Africa (Pty) Ltd, Private Bag X119, Bryanston, 2021, Tel: +27 11 510 9300, Fax: +27 11 510 9301, if you have questions or if you wish to receive further information.

Patients and health care professionals may obtain additional information from www.lilly.com or may call Dr. O. Mahanjana, Director Corporate Affairs, Pricing, Reimbursement and Access, Tel: +27 11 510 9492 or +27 82 416 2585

Yours Faithfully,

Dr. O.K. Kleivenes MD
Medical Director